# Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

> **NCT03430466** · PHASE2 · TERMINATED · sponsor: **Kyoto Breast Cancer Research Network** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Durvalmab&Tremelimumab&Fulvestrant

## Key facts

- **NCT ID:** NCT03430466
- **Lead sponsor:** Kyoto Breast Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-22
- **Primary completion:** 2018-01-30
- **Final completion:** 2018-07-31
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Recruiting was not possible
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430466, "Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03430466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*